Bardia Hajikarimloo, Ibrahim Mohammadzadeh, Salem M Tos, Rana Hashemi, Mohammad Amin Habibi, Arman Hasanzade, Sara Bana, Mahdi Hooshmand, Fatemeh Ghorbanpouryami, Dorsa Najari, Ehsan Bahrami Hezaveh
{"title":"Endovascular treatment of intracranial aneurysms with silk vista baby flow diverter: A systematic review and meta-analysis.","authors":"Bardia Hajikarimloo, Ibrahim Mohammadzadeh, Salem M Tos, Rana Hashemi, Mohammad Amin Habibi, Arman Hasanzade, Sara Bana, Mahdi Hooshmand, Fatemeh Ghorbanpouryami, Dorsa Najari, Ehsan Bahrami Hezaveh","doi":"10.1177/19714009251324324","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The Silk Vista Baby (SVB) flow diverter (FD) is a stent designed for small vessels ranging from 1.5 to 3.5 mm. It is the only FD deliverable through a 0.017-inch microcatheter. This systematic review and meta-analysis aimed to assess the SVB utilization in intracranial aneurysms (IAs).</p><p><strong>Methods: </strong>Four electronic databases, PubMed, Scopus, Embase, and Web of Science, were searched from inception to November 5<sup>th</sup>, 2024.</p><p><strong>Results: </strong>Ten studies with 359 patients with 373 IAs were included. Our results revealed a pooled complete occlusion rate of 65% (95%CI: 43%-83%), a favorable outcome rate of 94% (95%CI: 83%-100%), and a morbidity rate of 4% (95%CI: 0%-11%). Our meta-analysis revealed a pooled in-stent thrombosis rate of 2% (95%CI: 1%-5%), side branch occlusion rate of 2% (95%CI: 0%-3%), intracerebral hemorrhage (ICH) rate of 2% (95%CI: 1%-4%), and device shortening rate of 4% (95%CI: 3%-6%). The subgroup analysis showed that the complete occlusion rate (≤6: 84% [95%CI: 49%-100%] vs >6: 58% [95%CI: 41%-73%], <i>p</i> < .001) was higher in studies with 6-month or lower follow-up duration, and the favorable outcome rate was higher in those with greater than 6-month duration (≤6: 84% [95%CI: 73%-93%] vs >6: 97% [95%CI: 82%-100%], <i>p</i> < .001).</p><p><strong>Conclusion: </strong>SVB is an efficient and safe therapeutic option for managing IAs. We demonstrated that it is associated with promising clinical and radiological outcomes and low rates of complications.</p>","PeriodicalId":47358,"journal":{"name":"Neuroradiology Journal","volume":" ","pages":"19714009251324324"},"PeriodicalIF":1.3000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869223/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroradiology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/19714009251324324","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROIMAGING","Score":null,"Total":0}
引用次数: 0
摘要
背景：Silk Vista Baby（SVB）血流分流器（FD）是一种专为 1.5 至 3.5 毫米的小血管设计的支架。它是唯一可通过 0.017 英寸微导管输送的分流支架。本系统综述和荟萃分析旨在评估 SVB 在颅内动脉瘤（IAs）中的使用情况：方法：检索了 PubMed、Scopus、Embase 和 Web of Science 四个电子数据库，检索时间从开始到 2024 年 11 月 5 日：结果：共纳入 10 项研究，359 名患者，373 个动脉瘤。结果显示，汇总的完全闭塞率为 65%（95%CI：43%-83%），良好预后率为 94%（95%CI：83%-100%），发病率为 4%（95%CI：0%-11%）。我们的荟萃分析显示，支架内血栓形成率为 2%（95%CI：1%-5%），侧支闭塞率为 2%（95%CI：0%-3%），脑内出血（ICH）率为 2%（95%CI：1%-4%），装置缩短率为 4%（95%CI：3%-6%）。亚组分析显示，随访时间为6个月或更短的研究中完全闭塞率更高（≤6：84% [95%CI：49%-100%] vs >6：58% [95%CI：41%-73%]，P < .001），随访时间超过6个月的研究中良好结局率更高（≤6：84% [95%CI：73%-93%] vs >6：97% [95%CI：82%-100%]，P < .001）：结论：SVB 是一种有效、安全的治疗IAs的方法。结论：SVB 是治疗 IAs 的一种高效、安全的治疗方法。我们的研究表明，它具有良好的临床和放射学效果，并发症发生率低。
Endovascular treatment of intracranial aneurysms with silk vista baby flow diverter: A systematic review and meta-analysis.
Background: The Silk Vista Baby (SVB) flow diverter (FD) is a stent designed for small vessels ranging from 1.5 to 3.5 mm. It is the only FD deliverable through a 0.017-inch microcatheter. This systematic review and meta-analysis aimed to assess the SVB utilization in intracranial aneurysms (IAs).
Methods: Four electronic databases, PubMed, Scopus, Embase, and Web of Science, were searched from inception to November 5th, 2024.
Results: Ten studies with 359 patients with 373 IAs were included. Our results revealed a pooled complete occlusion rate of 65% (95%CI: 43%-83%), a favorable outcome rate of 94% (95%CI: 83%-100%), and a morbidity rate of 4% (95%CI: 0%-11%). Our meta-analysis revealed a pooled in-stent thrombosis rate of 2% (95%CI: 1%-5%), side branch occlusion rate of 2% (95%CI: 0%-3%), intracerebral hemorrhage (ICH) rate of 2% (95%CI: 1%-4%), and device shortening rate of 4% (95%CI: 3%-6%). The subgroup analysis showed that the complete occlusion rate (≤6: 84% [95%CI: 49%-100%] vs >6: 58% [95%CI: 41%-73%], p < .001) was higher in studies with 6-month or lower follow-up duration, and the favorable outcome rate was higher in those with greater than 6-month duration (≤6: 84% [95%CI: 73%-93%] vs >6: 97% [95%CI: 82%-100%], p < .001).
Conclusion: SVB is an efficient and safe therapeutic option for managing IAs. We demonstrated that it is associated with promising clinical and radiological outcomes and low rates of complications.
期刊介绍：
NRJ - The Neuroradiology Journal (formerly Rivista di Neuroradiologia) is the official journal of the Italian Association of Neuroradiology and of the several Scientific Societies from all over the world. Founded in 1988 as Rivista di Neuroradiologia, of June 2006 evolved in NRJ - The Neuroradiology Journal. It is published bimonthly.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
